文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急诊科检测直接口服抗凝药(利伐沙班与阿哌沙班)的新方法

A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting.
PubMed 文献 · Crit Care Explor · 2019-08-20
一句话结论i-II-X微流控检测在急诊患者中检测Xa因子抑制剂灵敏度95.20%、特异度100.00%,可弥补PT/INR的不足。

本研究为首次人体、91例患者、单中心回顾性先导研究,在急诊科对接受临床医生开具凝血试验的成年患者血浆样本,用新型微流控i-II-X检测过去24小时内阿哌沙班或利伐沙班的使用,并与PT、INR及利伐沙班抗Xa检测比较。i-II-X检测DOAC的灵敏度为95.20%、特异度为100.00%;与PT和INR不同,i-II-X能可靠识别因Xa因子抑制剂导致凝血时间延长的患者。作者认为该检测克服了现有凝血试验的局限,可能成为急诊和重症环境中常规筛查DOAC的有用工具,尤其适用于病历不可得或侵入性操作前需采取预防措施(如给予特异性逆转剂)的情况。

要点

  • i-II-X微流控检测在急诊患者血浆中检测Xa因子抑制剂(阿哌沙班、利伐沙班)的灵敏度为95.20%,特异度为100.00%。
  • 与PT和INR不同,i-II-X能可靠识别因Xa因子抑制剂存在导致凝血时间延长的患者。
  • 该检测适用于病历不可得或侵入性操作前需评估DOAC暴露的急诊场景。
  • 研究为91例患者、单中心回顾性先导研究,作者认为i-II-X可能成为急诊和重症常规筛查DOAC的工具。

适用人群与场景

  • 急诊科收治的成年患者,且接受了临床医生开具的任何需要3.2%缓冲枸橼酸钠采血管的凝血试验。

诊断标准与关键阈值

  • 使用i-II-X微流控检测筛查过去24小时内使用Xa因子抑制剂(包括阿哌沙班和利伐沙班)的情况。

研究设计与关键结果

  • 研究类型为首次人体、91例患者、单中心回顾性先导研究,设置于急诊科,无干预。
  • i-II-X检测急诊样本中DOAC的灵敏度为95.20%,特异度为100.00%。
  • 与PT和INR不同,i-II-X能可靠识别因Xa因子抑制剂存在导致凝血时间延长的患者。

证据类型、等级与局限

  • 证据类型:首次人体、91例患者、单中心回顾性先导研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为i-II-X检测克服了现有凝血试验的局限,可能成为急诊和重症环境中常规筛查DOAC的有用工具。
  • 作者认为该诊断方法在病历可能不可得或侵入性干预前需采取预防措施(如给予特异性逆转剂)的临床情境中尤其 relevant。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Determining whether a patient has taken a direct oral anticoagulant (DOAC) is critical during the periprocedural and preoperative period in the emergency department. However, the inaccessibility of complete medical records, along with the generally inconsistent sensitivity of conventional coagulation tests to these drugs, complicates clinical decision making and puts patients at risk of uncontrollable bleeding. In this study, we evaluate the utility of inhibitor-II-X (i-II-X), a novel, microfluidics-based diagnostic assay for the detection and identification of Factor Xa inhibitors (FXa-Is) in an acute care setting.

DESIGN: First-in-human, 91-patient, single-center retrospective pilot study.

SETTING: Emergency room.

PATIENTS: Adult patients admitted into the emergency department, which received any clinician-ordered coagulation test requiring a 3.2% buffered sodium citrate blood collection tube.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Plasma samples from patients admitted to the emergency department were screened for the use of FXa-Is, including apixaban and rivaroxaban, within the past 24 hours using our new i-II-X microfluidic test. i-II-X results were then compared with results from conventional coagulation tests, including prothrombin time (PT) and international normalized ratio (INR), which were ordered by treating clinicians, and an anti-Xa assay for rivaroxaban. The i-II-X test detected DOACs in samples collected from the emergency department with 95.20% sensitivity and 100.00% specificity. Unlike PT and INR, i-II-X reliably identified patients who had prolonged clotting times secondary to the presence of a FXa-I.

CONCLUSIONS: The i-II-X test overcomes the limitations of currently available coagulation tests and could be a useful tool by which to routinely screen patients for DOACs in emergency and critical care settings. Our new diagnostic approach is particularly relevant in clinical situations where medical records may be unavailable, or where precautions need to be taken prior to invasive interventions, such as specific reversal agent administration.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Frydman GH, Ellett F, Van Cott EM, et al. A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting. Crit Care Explor. 2019. PMID: 32166266. doi:10.1097/CCE.0000000000000024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。